75 results about "Senile macular degeneration" patented technology

Surgical apparatus and surgical methods are proposed for the prevention of age-related macular degeneration (AMD) and choroidal neovascularization (CNV), and other eye diseases such as glaucoma by removal of the sclera tissue to reduce its rigidity and increase the flood flow and decrease pressure in the choriocapillaris. The disclosed preferred embodiments of the system consists of a tissue ablation means and a control means of ablation patterns and a fiber delivery unit. The basic laser beam includes UV lasers and infrared lasers having wavelength ranges of (0.15-0.36) microns and (0.5-3.2) microns and diode lasers of about 0.98, 1.5 and 1.9 microns. AMD and CNV are prevented, delayed or reversed by using an ablative laser to ablate the sclera tissue in a predetermined patterns outside the limbus to increase the elasticity of the sclera tissue surrounding the eye globe The surgery apparatus also includes non-laser device of radio frequency wave, electrode device, bipolar device and plasma assisted device

An opthalmic spectacle or contact sharp cut-on orange lens that improves visual acuity and substantially reduces eye damage in a bright sunlit environment. The lenses substantially eliminate ultraviolet radiation and blue light shorter than .[.515.]. .Iadd.520 .Iaddend.nm. The ultraviolet radiation has been implicated as a cause of cateractogenisis. The blue light is implicated in senile macular degenerations, night blindness and snow blindness. The lens is substantially transparent to wavelengths greater than .[.636.]. .Iadd.600 .Iaddend.nm which are most useful for high visual acuity in bright sunlit environment.

The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.

The invention provides a human anti-vascular endothelial cell growth factor (VEGF) antibody as well as a coding gene and an application thereof. According to the invention, by virtue of genetic engineering means and a phage surface display technology, an anti-VEGF genetic engineering single-chain antibody is screened from a complete synthesis single-chain human antibody library, a variable region gene sequence of the anti-VEGF genetic engineering single-chain antibody is obtained, amino acids in a CDR (complementary determining region) of the anti-VEGF genetic engineering single-chain antibody are transformed by virtue of bioinformatics means, and finally a series of high-affinity anti-VEGF antibodies are obtained by constructing and screening mutation libraries and utilizing a chain exchange method, wherein affinity of the anti-VEGF antibodies with human VEGF is 10<-9>-10<-11>M. According to the invention, identification on immunocompetence and biological activity of the antibody is completed, the anti-VEGF antibody is verified to have the characteristic of being antagonistic to combination of VEGF and VEGFR2 and can effectively inhibit proliferation of vascular endothelial cells induced by VEGF. The invention provides a new specific candidate antibody molecule for resisting tumour and senile macular degeneration targeted by VEGF in future.

The invention relates to the technical field of medicines and in particular relates to a novel chlorine photosensitizer-pyropheophorbide-a ether amino acid derivative, a preparation method thereof and an application to preparation of antitumor medicines. A chemical structure of the pyropheophorbide-a ether amino acid derivative is shown in a general formula (I) in the specification. The pyropheophorbide-a ether amino acid derivative has the advantages of high efficiency, low toxicity and the like, and can be used for preparing new medicines for photodynamic therapy of cancers, medicines for photodynamic therapy of benign vascular diseases, such as age-related macular degeneration and nevus flammeus and medicines for photodynamic therapy of condyloma acuminate.

The invention discloses an eyesight improving lutein capsule comprising the following raw materials in parts by weight: 20-30 parts of zinc gluconate, 10-14 parts of lutein, 0.2-0.8 part of vitamin A, 10-14 parts of vitamin C, 2-4 parts of vitamin E, 140-160 parts of soybean oil and 5-15 parts of bee wax. The eyesight improving lutein capsule disclosed by the invention is rich in nutrition and good in taste, and not only has the effects of relieving visual fatigue and improving eyesight, but also has the effects of preventing dry eye syndrome, myopia, age-related macular degeneration and the like.

The invention provides a kit for detecting senile macular degeneration disease, comprising a related reagent selected freely from rs1061170 variation of exon 9, rs1329428 variation of intron 15, rs800292 variation of exon 2 used for detecting CFH gene and / or rs3753394 variation in a 5' non-coding region used for AMD screening diagnosis. By detecting whether the above locus has variation or not, the kit can detect that risk of senile macular degeneration disease has high association with AMD, and can be used for monitoring and detecting AMD high risk group at an early stage so as to implement early-stage prevention and curing and reduce vision damage to AMD high risk group.

The invention relates to the technical field of artificial intelligence, and provides a fundus image recognition method and device, fundus image recognition equipment and a storage medium. The methodcomprises: obtaining an fundus image; extracting first target data from the fundus image, and performing redundancy elimination processing on the first target data to obtain a first central concave feature; generating a macular area mask according to the first central concave feature; intercepting a macular area in the fundus image through a macular area mask to obtain a macular area image; and identifying senile macular degeneration lesion features in the macular area image, and classifying the macular area image according to the senile macular degeneration lesion features. The macular area image is cut from the fundus image through the mask generation model, the macular area image is classified according to AMD focus features in the macular area image, feature data in the macular area image is obvious and easy to recognize, and therefore the classification accuracy of the fundus image is effectively improved.

The present invention discloses one kind of composite soft lutein capsule and its preparation process. The content in each capsule includes lutein1-10 mg, alpha-linolenic acid 100-300 mg, vitamin A 0-5 mg and vitamin E 0-7.5 mg; and the capsule covering consists of gelatin, glycerin, water, and opacifier or edible color. The lutein is prepared through supercritical CO2 extraction process, and has no pollutant and organic solvent residue. The composite soft lutein capsule product has stable quality and high bioavailability, and has certain preventing and treating effect on senile macular degeneration, cataract and cardiac and cerebral vascular diseases.

The invention relates to novel chlorin e6 derivatives, pharmaceutically acceptable salts thereof, as well as preparation methods and applications of the novel chlorin e6 derivatives and the pharmaceutically acceptable salts and belongs to the technical field of medicines. The chlorin e6 ether amino acid derivatives comprise compounds shown as the general structural formula I and optical isomers ofthe general structural formula I. The preparation method of the novel chlorin e6 derivatives comprises steps as follows: 3-vinyl in chlorin e6 is etherified, and 15-ethylcarboxyl and amino acid are subjected to peptides formation. The chlorin e6 ether amino acid derivatives and the pharmaceutically acceptable salts thereof can be taken as photodynamic antitumor drugs for application. Compared with an existing clinically applied similar photosensitizer talaporfin, the chlorin e6 ether amino acid derivatives have the advantages of being high in photodynamic antitumor activity, high in ratio ofdark toxicity to phototoxicity and the like and can be applied to preparation of new photodynamic antitumor drugs including photodynamic cancer treating drugs, photodynamic treatment drugs for benignvascular diseases such as senile macular degeneration and nevus flammeus as well as photodynamic treatment drugs for condyloma acuminate.

The present invention belongs to the field of biomedicine, and relates to a nanometer fiber polymer composite membrane, a preparation method and uses thereof. According to the nanometer fiber polymer composite membrane, the low layer is a hydrogel nanometer fiber membrane, the middle layer is a Matrigel matrix gel layer, and the upper layer is a retinal pigment epithelium layer. The nanometer fiber polymer composite membrane can be adopted as a bio-scaffold for supporting growth and transplantation of RPE cells, and has characteristics of softness, elasticity, good permeability, biodegradability and a structure similar to extracellular matrix, wherein adhesion and differentiation of the RPE monolayer cells and surgical procedure operations are easily achieved with the characteristics, and the nanometer fiber polymer composite membrane can be discharged out of a body through a metabolism process after transplantation so as not to generate harm to the human body. According to the present invention, a bio-nanometer material and cell engineering are combined, brightness and hope are provided for age-related macular degeneration (ARMD) patients with the successful research, and great economic benefits and social benefits are generated.

The invention relates to the technical field of medicines and particularly relates to a novel chlorin photosensitizer, i.e., a chlorin p6 amino acid derivative, a preparation method therefor and use of the chlorin p6 amino acid derivative in preparation of antitumor drugs. The chlorin p6 amino acid derivative disclosed by the invention has a chemical structure represented by a general formula (I) shown in the description. The chlorin p6 amino acid derivative disclosed by the invention has the advantages of high efficiency, low toxicity and the like and can be used for preparing novel photodynamic cancer therapy drugs, drugs for photodynamic therapy on benign vascular diseases such as senile macular degeneration and nevus flammeus and drugs for photodynamic therapy on verruca acuminata.

The current situation is such that it is difficult for drugs to reach posterior tissues of an eyeball, such as choroid and retina, with the result that treating diseases in such regions is difficult. Thus, how to attain effective delivery of drugs is of importance. It has been found that effective delivery of drugs to positerior tissues of the eyeball, such as choroid and retina, especially those wherein vascularization has occurred can be accomplished by systemic administration, especially intravenous administration of polymer micells having a drug incorporated therein. Further, it has been found that when a photosensitive substance is used as a drug and PDT is carried out, choroidal neo-vessels can be effectively choked so as to be useful for the treatment of age-related macular degeneration.

The present invention is the application of hypocrellin photosensitizer in pharmacy. Hypocrellin photosensitizer is used in preparing photodynamic medicine for treating nevus flammeus, senile macular degeneration and other blood capillary diseases.The said hypocrellin includes hypocrellin A, hypocrellin B and medicinal carrier. The present invention utilizes the photophysical and chemical features of hypocrellin photosensitizer, especially its maximum absorption spectrum value at 450-580 nm wavelength range, the light of which has effective penetrating depth of 1-2 mm to provide new clinicalindications for the hypocrellin.

The invention belongs to the technical field of edible blend oil, and particularly relates to edible blend oil containing lutein ester and a preparation method thereof. The edible blend oil containinglutein ester comprises the following components in percentage by mass: 83.7-93.5% of edible vegetable oil, 0.1-3.5% of lutein ester, 0.2-1.2% of carotene, 1.2-3.6% of antioxidant and 5-8% of composite unsaturated fatty acid. The edible blend oil containing lutein ester can obviously enhance the visual ability, increase the blood flow of the eyeballs and improve the eye muscle fatigue, thereby lowering the morbidity of cataract, senile macular degeneration and juvenile myopia. The edible blend oil containing lutein ester has the effects of resisting oxidation, lowering the cholesterol and thelike.

A method and system are described for controlling a therapeutic procedure performed on a patient. Based on patient-related information, control system (90) determines at least one dosage parameter and at least one application parameter of the therapeutic procedure. Display (117) displays one or more prompts instructing an operator to introduce at least one external substance into the patient in accordance with the at least one dosage parameter and displays one or more instructions to the operator to apply an output of an application device (80) to a treatment area (100) of the patient in accordance with the at least one application parameter. The therapeutic procedure may be an Indocyanine Green mediated photothrombosis treatment for age-related macular degeneration.

The invention relates to the technical field of medicines, and concretely relates to a novel dihydroporphine photosensitizer - purpurin-18 ether derivative, a preparation method thereof, and a use of the purpurin-18 ether derivative in the preparation of antitumor medicines. The chemical structure of the purpurin-18 ether derivative is represented by general formula (I) shown in the description. The purpurin-18 ether derivative has the advantages of high efficiency and low toxicity, and can be used for preparing new photodynamic therapy medicines of cancers, photodynamic therapy medicines of benign diseases, such as senile macula lutea denaturation and nevus flammeus, and photodynamic therapy medicines of condyloma acuminatum.

The invention relates to an eye health care product capable of preventing and delaying senile macular degeneration and a manufacture method. The eye health care product comprises ingredients by weight by part: 20 parts to 30 parts of chlorella extractives, 10 parts to 25 parts of kiwi fruit extractives, 15 parts to 20 parts of oyster extractives, 20 parts to 25 parts of pine bark extractives, 15 parts to 10 parts of kudzu vine root extractives and 10 parts to 15 parts of whinberry extractives. Compared with the prior art, the eye health care product capable of preventing and delaying senile macular degeneration has the advantages of effectively improving visual function, being accurate in effect and mechanism on health care function of visual function compared with other products sold in markets, and having excellent effects on preventing and curing other macular degeneration, diabetes mellitus complication fundus lesion and cataract.

A topical drug composition for the treatment of age-related maculopathy, age-rlated macular degeneration, ocular hypertension, glaucoma or other eye disease resulting from increased intraocular pressure comprising a solution of anabolic androgenic agent and 17-β-estradiol suspended or dissolved in a suitable ophthalmic vehicle is disclosed. In the preferred embodiment, 17-β-estradiol, or its esters, is in a lipid vehicle or 17-β-estradiol-3-phosphate, or other esters of 17-β-estradiol, is combined with an anabolic androgenic agent in an aqueous vehicle having a pH of between about pH 6 to pH 8. The composition is administered to the eye in an effective amount to maintain physiologic or normal intraocular pressure or to return elevated intraocular pressure to lower levels.

Provided are VEGF and PDGFRβ bispecific fusion protein and application thereof. More specifically, a bifunctional fusion protein comprising VEGFR extracellular ligand binding domain and PDGFRβ antibody fragment is provided, which can be used to treat wet age-related macular degeneration (AMD) and any other diseases that can be improved by inhibiting VEGF and PDGF signaling pathways , such as tumors and diabetic retinopathy.

The present invention is directed to the use of anercortave acetate or the alcohol thereof for the protection of visual acuity in patients with age related macular degeneration.

It is intended to provide a pharmaceutical product with a high therapeutic effect in the treatment of a retinal disease accompanied by angiogenesis such as age-related macular degeneration or diabetic retinopathy. A therapeutic agent for a retinal disease containing a substance that specifically inhibits the expression of HIF-1alpha and a substance that specifically inhibits the expression of HIF-2alpha. The inhibitor which is an active ingredient of the therapeutic agent of the invention is an RNAi-inducible nucleic acid, an antisense nucleic acid, or a ribozyme against HIF-1a and HIF-2a, or an expression vector therefor.

On the research basis that microbes of specific species are present in eyes of patients with different eye diseases, the invention discloses a method for establishing a model, and the method comprisesthe step of infecting a model carrier with the microbes. The model prepared by the method can be used for screening drugs for the eye diseases, and the eye diseases include senile macular degeneration, the behcet disease, the Vogt-Koyanagi-Harada syndrome, uveitis, retinopathy, xerophthalmia, sympathetic ophthalmia, trachoma, cataract, conjunctivitis, chalazion, glaucoma, muscae volitantes and the like.

The invention discloses a traditional Chinese medicine preparation for treating senile macular degeneration. The traditional Chinese medicine considers that senility is related to the kidney, the pupil belongs to the kidney, and the macula lutea is positioned in the center of the eye ground and belongs to spleen-earth. The senile macular degeneration comprises the clinical accompanied symptoms such as bleeding, tunica vasculosa and choroid wart and belongs to vein stagnation. The traditional Chinese medicine preparation is prepared by selecting the following traditional Chinese medicines to decoct into decoction: forestry greenstar root, Szechwan-Yunnan sanicle root, gordon euryale root, Chinese evergreenchinkapin seed, common pistache fruit, riparian greenbrier root and rhizome, Japanese Metaplexis, Chinese astilbe rhizome, yellow angledtwig magnoliavine root, sago frond and water. According to the clinical test, the traditional Chinese medicine preparation is obvious in curative effect and is worthy of clinical popularization and application.

This invention relates to a pyrido[3,4-d]pyrimidine derivative of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, L1, L2, V, L3, and R2 are as defined in the specification, that inhibits a matrix metalloproteinase-13 enzyme and thus is useful for treating diseases resulting from MMP-13 mediated tissue breakdown such as osteoarthritis, rheumatoid arthritis, cartilage damage, psoriatic arthritis, ankylosing spondylitis, heart failure, atherosclerosis, inflammatory bowel disease, multiple sclerosis, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, cancer, and osteoporosis.

The invention discloses a near-infrared fundus therapeutic instrument, and relates to the technical field of medical instruments for eye diseases. The near-infrared fundus therapeutic instrument comprises a head-mounted main body and a controller, wherein the head-mounted main body is provided with a near-infrared light source electrically connected with the controller, the near-infrared light source is used for irradiating the fundus of a tested user, the near-infrared light source has a plurality of preset light emitting powers, and the controller is used for controlling the near-infrared light source to select the corresponding preset light emitting power so as to adapt to the fundus disease condition of the tested user. The near-infrared fundus therapeutic instrument can conveniently and effectively assist in treating fundus diseases such as central serous retinitis, senile macular degeneration, and the like.

Disclosed are improved peptides for inhibiting angiogenesis, Ac-RLYE (SEQ ID NO: 1) and R(D)LYE (SEQ ID NO: 6), and a composition for the prevention and treatment of cancers and diseases related to angiogenesis comprising the peptides as an active ingredient. A peptide for inhibiting angiogenesis is disclosed wherein the L-Arg of an N-terminal is acetylated in a peptide consisting of an amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 1). A peptide for inhibiting angiogenesis is disclosed wherein L-Arg is substituted with D-Arg in a peptide consisting of the amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 6). Methods for using a composition comprising the peptides as active ingredients for the prevention or treatment of diseases (cancer, diabetic retinopathy or senile macular degeneration) caused by excessive angiogenesis are also disclosed. The peptides have a long half-life and are excellent in VEGF-induced angiogenesis inhibitory effect.